Compare Eli Lilly And Co (LLY) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs ON Holding AG — how do they compare? Eli Lilly And Co trades at $1,177.1 (market cap $1.04T), while ON Holding AG trades at $35 (market cap $11.38B). The key difference: Eli Lilly And Co is far larger — about 91.4× ON Holding AG's market cap, and Eli Lilly And Co pays a 0.59% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and ON Holding AG for 22 Days on average.
| LLY | ONON | |
|---|---|---|
Market Cap | $1.04T | $11.38B |
Volume | 3,064,878 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $50.63 |
52-Week Low | $799.57 | $26.76 |
Typical Hold Time | 93 Days | 22 Days |
Enterprise Value | $1.09T | $10.54B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
ONON trades at $34.99, up 5.33% with strong bullish momentum. The stock shows robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 beating expectations of $0.42. Technical indicators show bullish moving averages but overbought RSI conditions. Recent investor day announcements of a $1 billion buyback and ambitious 2029 targets have driven positive sentiment.
Outlook remains positive with analyst consensus at $42.26 target (21% upside) and 74% buy ratings. Key opportunities include DTC growth and margin expansion, while risks include execution on growth targets and competitive pressures in the athletic footwear sector. The stock trades at reasonable valuations with P/E of 24.02 and EV/EBITDA of 14.79.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
